Pfizer to Build $465M Pharmaceutical Plant in U.S.

American pharmaceutical firm Pfizer debuted plans to build one of the most advanced sterile injectable pharmaceutical manufacturing facilities in the world on Tuesday as the drug maker looks to meet rising global demand for sterile injectable, liquids, and semi-solid medicine products. 

Located in Portage, MI, the $465 million Modular Aseptic Processing (MAP) facility will include advanced aseptic manufacturing technology in several contained modular manufacturing lines, the company said in a press release.

“Sterile drug product manufacturing is incredibly complex. This contemporary facility will combine cutting edge technology and a highly talented workforce to assure we remain a trusted and reliable supplier of these therapies to patients,” said Ron Perry, site leader at the Portage plant, in a statement. 

The project expands on Pfizer’s existing presence in Portage, which includes a plant that currently serves as the main global supplier of the company’s Active Pharmaceutical Ingredients (APIs) and sterile injectable, liquid, and semi solid drugs.

“This investment will strengthen Pfizer’s leadership in sterile manufacturing technology and help meet growing patient demand,” Kirsten Lund-Jurgensen, executive vice president and president of Pfizer Global Supply, said in the firm’s release. “It will also create hundreds of highly skilled jobs, fortifying Michigan’s high-tech manufacturing environment.”

Pfizer said it expects to create about 450 jobs at the new facility over the coming years. Construction of the new facility in Michigan is slated to reach completion in 2021, with production expected to start in 2024.

For more news headlines, articles, and equipment reviews, visit our Equipment Zones